Breaking News

Envigo Launches Hepatotoxicity Testing

In vitro program aims to predict the likelihood of compounds causing drug induced livery injury

Envigo has launched a program of in vitro technologies aimed at helping to predict the likelihood of compounds causing drug induced livery injury (DILI) – one of the major causes of drugs being withdrawn from the market.
 
The new DILI Assessment program can help identify whether a drug exhibits possible risk factors associated with hepatotoxicity. The program can be run in full, using all of its tests, or can be conducted using single assays as required.
 
“Envigo’s battery of in vitro tests, typically using human cells, enables our customers to determine if a compound carries a DILI liability. A compound that is negative in our in vitro testing program is considerably de-risked from one of the failure factors newly approved drugs face. This allows our customers to make more informed choices as to whether they should progress the compound. The de-risking approach serves to increase patient safety, provides confidence to invest and aids the in/out-licensing of new drugs,” said Guy Webber, Scientific Manager of the In Vitro and Drug-Drug Interaction Sciences Group at Envigo.
 
The technologies in the new DILI assessment program consist of three key tests – covalent binding, reactive metabolite formation and time dependent inhibition (TDI) of cytochrome (CYP) enzymes. According to the company, these are fast turnaround in vitro assays with low compound usage – requiring just milligrams of material, making them ideal for early discovery research, where typically only small amounts of compound are available.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters